Top Story

Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting

Highlights from the 2015 <i>HemOnc Today</i> Melanoma and Cutaneous Malignancies meeting
April 26, 2015

NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of hematology and oncology at St. Luke’s Cancer Center in Bethlehem, Pennsylvania, and a HemOnc Today Editorial Board member, discusses highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting.

“This is meeting not just for melanoma specialists, so to speak, but also for a regular, busy oncologist or hematologist that sees some melanoma and skin cancers in their practice and would like to get a very practical update of state-of-the-art information, but presented in a manner that is understandable and applicable to clinical practice,” Agarwala told HemOnc Today.

Meeting News Coverage

Next generation sequencing increases actionable mutation detection in malignant melanoma

April 26, 2015
NEW YORK — The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations among patients with…
Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma Meeting News CoverageVideo

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University, presents data from patients with melanoma who were…
Meeting News Coverage

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015
NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or…
Meeting News Coverage

Algorithm predicts HCC in patients with cirrhosis

April 25, 2015
VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan